NCT03560479 - A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2023

Conditions

Non-muscle Invasive Bladder Cancer

Interventions

DRUG

alpha1H, 7.4 mg/mL

Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)

OTHER

placebo

Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)

DRUG

alpha1H, 37 mg/mL

Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)

DRUG

alpha1H, 74 mg/mL

Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)

Trial Locations (1)

RECRUITING

Motol University Hospital, Prague